메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval fo…

HANGZHOU, China, March 14, 2026 -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis (MASH), by the China's Center for Drug Evaluation (CDE). This achievement represents the second clinical indication for the company's lead drug candidate, complementing its ongoing development program for Parkinson's disease. This approval constitutes the first glob
- 김갑성 기자
- 2026-03-14 12:33
Biophytis-LynxKite Alliance Expands to Turbocharge AI-drive…

[ 메디채널 김갑성 기자 ] Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research Next-generation drug candidates against sarcopenia Next generation drug candidates for dry age-related macular degeneration SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 -- Lynxkite is expanding its partnership with Biophyti
- 김갑성 기자
- 2026-03-13 23:40
Insilico Medicine to Announce 2025 Financial Results on Ma…

CAMBRIDGE, Mass., March 13, 2026 -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for the year ended December 31, 2025, and provide a business update on March 30, 2026. The Company will hold live conference calls in English and Mandarin on March 30, 2026, Beijing Time. The English session of the conference call will be held at 9:00 AM on March 30, 2026, Beijing Time (9:00
- 김갑성 기자
- 2026-03-13 21:59
CityUHK researchers unveil the mystery of "Asian Flush" mech…

HONG KONG, March 13, 2026 -- Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known as "Asian Flush Syndrome". This ALDH2 genetic mutation is more than just a metabolic defect; it conceals a deadly cardiovascular risk. While the medical community has long observed that carriers of this mutation suffer more severe heart damage during a myocardial infarction (heart attack), the specific underlying mechanism has remained a mystery until now. A research team led by Professor Yin Huiyong, Professor in the Department of Biomedical Sciences
- 김갑성 기자
- 2026-03-13 21:30
Unixell Biotech receives IND clearance by FDA for its Allogenei…

SHANGHAI, March 13, 2026 -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthrough marks UX-GIP001 as the first iPSC-derived allogeneic epilepsy cell therapy approved in the U.S. and simultaneously establishes it as China's pioneering cell therapy for epilepsy to advance into the clinical stage. Epilepsy is a common neurological disorder affecting over 70 million people worldwide. It
- 김갑성 기자
- 2026-03-13 20:06
POMDOCTOR LIMITED Announces Strategic Upgrade, Focusing…

GUANGZHOU, China, March 13, 2026 -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-grade smart wearables + full-cycle chronic disease management". The Company plans to accelerate related technology research and development ("R&D") and scenario-based implementation by leveraging its extensive medical resources and strong compliance capabi
- 김갑성 기자
- 2026-03-13 20:00
Esaote at EAU 2026: Introducing Exclusive PAM Technology to…

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth LONDON, March 13, 2026 -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is reinforcing its position as a leading provider of advanced imaging and guided therapy solutions for urologists at the 41st Annual European Association of Urology (EAU) Congress, currently underway in London (13-16 March 2026). Esaote presents its new and i
- 김갑성 기자
- 2026-03-13 19:00
에사오테, EAU 2026에서 정밀 비뇨기 영상 발전 위한 독점 PAM 기술 공개

새 MyLab™E85 GTS Edition에 이 기술 적용…에사오테 부스에서 MyLab™C30 GTS 초음파 시스템과 함께 전시 런던, 2026년 3월 13일 -- 초음파, 전용 MRI, 의료 IT 등 의료 영상 분야의 이탈리아 혁신 기업 에사오테 그룹(Esaote Group)이 2026년 3월 13일부터 16일까지 런던에서 열리고 있는 제41회 유럽비뇨기학회 연례 학술대회(41st Annual European Association of Urology Congress, EAU)에서 비뇨기 전문의용 첨단 영상 및 유도 치료 솔루션 제공 기업으로서 입지를 강화하고 있다. 에사오테는 비뇨기 분야를 위한 새로운 혁신 기술인 독점 전립선 어텐션 맵(Prostate Attention Map, PAM)을 선보였다. 새로 나온 MyLab™E85 GTS에 적용된 기술이다. 에사오테는 또 신제품 MyLab™C30 GTS 초음파 시스템도 공개할 예정이다. 이 시스템은 휴대형 장비에서도 높은 영상 품질을 제공해 다양한 검사 환경에 대응할 수 있도록 설계됐다. 에사오테(부스 N16)는 학회 기간에 전립선 진단 정
- 김갑성 기자
- 2026-03-13 19:00
Everest Medicines' Licensing Partner NovaBridge and Visar…

[ 메디채널 김갑성 기자 ] VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD VIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm Potentially best-in-class durability with a favorable safety profile and no dose-limiting toxicity Phase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027 SHANGHAI, March 13, 2
- 김갑성 기자
- 2026-03-13 18:05
Tetra Pak: Natural Ingredients and Emotional Drivers Reshap…

[ 메디채널 김갑성 기자 ] 62% of APAC consumers prioritise supporting physical health when choosing FSN products. 61% use FSN products to ensure their daily nutritional needs are met. 48% look for solutions that help maintain healthy energy levels throughout a busy day. 21% value convenience on the go, while 19% use FSN products to save time on meals or snacks. SINGAPORE, March 13, 2026 -- The global food supplements and nutrition (FSN) market, spanning protein-enriched beverages, fortified drinks and functional supplements, is projected to reach approximately USD$758.99 billion by 203
- 김갑성 기자
- 2026-03-13 13:41

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-14_SAT

2026-03-13_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 14일 19시 40분